Post-mastectomy radiation therapy: Translating local benefits into improved survival

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 78-83

  Chung, Christine S ^a,b   Harris, Jay R ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Breast cancer; Post mastectomy radiation therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; PLACEBO; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE EXACERBATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HEART DEATH; HEREDITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG TOXICITY; LYMPH NODE METASTASIS; LYMPHEDEMA; MASTECTOMY; METASTASIS POTENTIAL; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SELECTION; PNEUMONIA; POSTMENOPAUSE; POSTOPERATIVE CARE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION HAZARD; RECURRENCE RISK; RECURRENT CANCER; RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 35648965137     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.07.018     Document Type: Article

References (64)

1. Harris JR, Lippman ME, Morrow M, et al., editors. Diseases of the breast. Philadelphia, 2004.
2. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337 14 (1997) 949-955
3. Overgaard M., Jensen M.B., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353 9165 (1999) 1641-1648
4. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337 14 (1997) 956-962
5. Ragaz J., Olivotto I.A., Spinelli J.J., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97 2 (2005) 116-126
6. Punglia R.S., Morrow M., Winer E., and Harris J.R. Local therapy and survival in breast cancer. N Engl J Med 356 23 (2007) 2399-2405
7. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355 9217 (2000) 1757-1770
8. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 333 22 (1995) 1444-1455
9. Harris J.R., Halpin-Murphy P., McNeese M., Mendenhall N.P., Morrow M., and Robert N.J. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 44 5 (1999) 989-990
10. Whelan T.J., Julian J., Wright J., Jadad A.R., and Levine M.L. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18 6 (2000) 1220-1229
11. El-Tamer M., Homel P., and Braverman A.S. Radiotherapy and chemotherapy in high-risk breast cancer. N Engl J Med 338 5 (1998) 329 author reply 31-2
12. Goldhirsch A., Coates A.S., Colleoni M., and Gelber R.D. Radiotherapy and chemotherapy in high-risk breast cancer. N Engl J Med 338 5 (1998) 330-331 author reply 1-2
13. Recht A., Edge S.B., Solin L.J., et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 5 (2001) 1539-1569
14. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 9503 (2005) 2087-2106
15. Nielsen H.M., Overgaard M., Grau C., Jensen A.R., and Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 24 15 (2006) 2268-2275
16. Wapnir I.L., Anderson S.J., Mamounas E.P., et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24 13 (2006) 2028-2037
17. Elkhuizen P.H., Hermans J., Leer J.W., and van d E.V.M.J. Isolated late local recurrences with high mitotic count and early local recurrences following breast-conserving therapy are associated with increased risk on distant metastasis. Int J Radiat Oncol Biol Phys 50 2 (2001) 387-396
18. Haffty B.G., Reiss M., Beinfield M., Fischer D., Ward B., and McKhann C. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol 14 1 (1996) 52-57
19. Meric F., Mirza N.Q., Vlastos G., et al. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer 97 4 (2003) 926-933
20. Vicini F.A., Kestin L., Huang R., and Martinez A. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy?. Cancer 97 4 (2003) 910-919
21. Whelan T., Clark R., Roberts R., Levine M., and Foster G. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group. Int J Radiat Oncol Biol Phys 30 1 (1994) 11-16
22. Smith T.E., Lee D., Turner B.C., Carter D., and Haffty B.G. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 48 5 (2000) 1281-1289
23. Goldstein N.S., Vicini F.A., Hunter S., et al. Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: comparison with clinical and biologic factors. Am J Clin Pathol 123 5 (2005) 679-689
24. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
25. Fisher B., Bryant J., Dignam J.J., et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20 20 (2002) 4141-4149
26. Fyles A.W., McCready D.R., Manchul L.A., et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351 10 (2004) 963-970
27. Contents of Lancet website material for EBCTCG local therapy comparisons, Webfigure 6b, 〈http://www.ctsu.ox.ac.uk/~ebctcg/local2000/annex.pdf〉;2006 [accessed 19.02.07].
28. Marks L.B., and Prosnitz L.R. Postoperative radiotherapy for lung cancer: the breast cancer story all over again?. Int J Radiat Oncol Biol Phys 48 3 (2000) 625-627
29. Recht A., Bartelink H., Fourquet A., et al. Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol 16 8 (1998) 2886-2889
30. Olivotto I.A., Truong P.T., and Chua B. Postmastectomy radiation therapy: who needs it?. J Clin Oncol 22 21 (2004) 4237-4239
31. Truong P.T., Olivotto I.A., Whelan T.J., and Levine M. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 170 8 (2004) 1263-1273
32. Ceilley E., Jagsi R., Goldberg S., et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys 61 2 (2005) 365-373
33. Whelan T., and Levine M. More evidence that locoregional radiation therapy improves survival: what should we do?. J Natl Cancer Inst 97 2 (2005) 82-84
34. Fowble B., Gray R., Gilchrist K., Goodman R.L., Taylor S., and Tormey D.C. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 6 7 (1988) 1107-1117
35. Kunkler IH, Price A, Dixon M, Canney P, Prescott R, Sainsbury R, et al. SUPREMO (Selective Use of Postoperative Radiotherapy after Mastectomy)-a phase III randomised trial assessing the role of postmastectomy chest wall irradiation in 'intermediate risk' women with operable breast cancer receiving adjuvant systemic therapy. In: International congress of radiation research. Brisbane, Australia, 2003 [poster abstract no. 1159].
36. Contents of Lancet website material for EBCTCG local therapy comparisons, Webfigure 2d-e, 〈http://www.ctsu.ox.ac.uk/~ebctcg/local2000/annex.pdf〉; 2006 [accessed 17.02.07].
37. Woodward W.A., Strom E.A., Tucker S.L., et al. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 57 2 (2003) 336-344
38. Katz A., Strom E.A., Buchholz T.A., et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 18 15 (2000) 2817-2827
39. Recht A., Gray R., Davidson N.E., et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 17 6 (1999) 1689-1700
40. Katz A., Strom E.A., Buchholz T.A., Theriault R., Singletary S.E., and McNeese M.D. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 50 3 (2001) 735-742
41. Wallgren A., Bonetti M., Gelber R.D., et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21 7 (2003) 1205-1213
42. Truong P.T., Olivotto I.A., Kader H.A., Panades M., Speers C.H., and Berthelet E. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 61 5 (2005) 1337-1347
43. Truong P.T., Olivotto I.A., Speers C.H., Wai E.S., Berthelet E., and Kader H.A. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer. Int J Radiat Oncol Biol Phys 58 3 (2004) 797-804
44. Huang E.H., Tucker S.L., Strom E.A., et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 62 2 (2005) 351-357
45. Huang E.H., Strom E.A., Perkins G.H., et al. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys 66 2 (2006) 352-357
46. Truong P.T., Berthelet E., Lee J., Kader H.A., and Olivotto I.A. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 103 10 (2005) 2006-2014
47. Cheng J.C., Chen C.M., Liu M.C., et al. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 52 4 (2002) 980-988
48. Ragaz J., and Jackson S.M. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation. Cancer 89 1 (2000) 223-225
49. Truong P.T., Yong C.M., Abnousi F., et al. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy. J Am Coll Surg 200 6 (2005) 912-921
50. Schoppmann S.F., Bayer G., Aumayr K., et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 240 2 (2004) 306-312
51. Pinder S.E., Ellis I.O., Galea M., O'Rouke S., Blamey R.W., and Elston C.W. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24 1 (1994) 41-47
52. Hasebe T., Sasaki S., Imoto S., and Ochiai A. Histological characteristics of tumor in vessels and lymph nodes are significant predictors of progression of invasive ductal carcinoma of the breast: a prospective study. Hum Pathol 35 3 (2004) 298-308
53. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 10 (2005) 1569-1583
54. Van den Eynden G.G., Van der Auwera I., Van Laere S.J., et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 94 11 (2006) 1643-1649
55. Arnaout-Alkarain A., Kahn H.J., Narod S.A., Sun P.A., and Marks A.N. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol (2007)
56. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826
57. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 25 (2002) 1999-2009
58. Nuyten D.S., Kreike B., Hart A.A., et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8 5 (2006) R62
59. Giordano S.H., Kuo Y.F., Freeman J.L., Buchholz T.A., Hortobagyi G.N., and Goodwin J.S. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97 6 (2005) 419-424
60. Chua B., Ung O., and Boyages J. Competing considerations in regional nodal treatment for early breast cancer. Breast J 8 1 (2002) 15-22
61. Coen J.J., Taghian A.G., Kachnic L.A., Assaad S.I., and Powell S.N. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 55 5 (2003) 1209-1215
62. Graham P., Jagavkar R., Browne L., and Millar E. Supraclavicular radiotherapy must be limited laterally by the coracoid to avoid significant adjuvant breast nodal radiotherapy lymphoedema risk. Australas Radiol 50 6 (2006) 578-582
63. Kreisman H., and Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol 19 5 (1992) 508-520
64. Johansson S., Svensson H., Larsson L.G., and Denekamp J. Brachial plexopathy after postoperative radiotherapy of breast cancer patients-a long-term follow-up. Acta Oncol 39 3 (2000) 373-382